About Multus
Multus is a company based in London (United Kingdom) founded in 2019 by Kevin Pan, Cai Linton, and Reka Tron. Multus has raised $9.3 million across 5 funding rounds from investors including UK Research and Innovation, European Union and Asahi Kasei. The company has 8 employees as of March 31, 2023. Multus operates in a competitive market with competitors including BioLife Solutions, RoosterBio, Shanghai Doning Biotechnology, ArunA Bio and Biotangents, among others.
- Headquarter London, United Kingdom
- Employees 8 as on 31 Mar, 2023
- Founders Kevin Pan, Cai Linton, Reka Tron
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Multus Biotechnology Limited
- Date of Incorporation 18 Mar, 2020
- Jurisdiction LONDON, UNITED KINGDOM
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$9.3 M (USD)
in 5 rounds
-
Latest Funding Round
$7 M (USD), Series A
Jan 16, 2023
-
Investors
UK Research and Innovation
& 10 more
-
Employee Count
8
as on Mar 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Multus
Unlock access to complete
Unlock access to complete
Funding Insights of Multus
Multus has successfully raised a total of $9.3M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $7 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $7.0M
-
First Round
First Round
(11 Jun 2020)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2023 | Amount | Grant - Multus | Valuation |
investors |
|
| Jan, 2023 | Amount | Series A - Multus | Valuation | Mandi Ventures , SOSV | |
| Jul, 2021 | Amount | Grant - Multus | Valuation |
investors |
Investors in Multus
Multus has secured backing from 11 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include UK Research and Innovation, European Union and Asahi Kasei.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in tech-enabled food chain sustainability startups.
|
Founded Year | Domain | Location | |
|
Venture capital and accelerator services are provided across multiple sectors.
|
Founded Year | Domain | Location | |
|
Investments are directed toward plant-based food innovations and technologies.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Multus
Financial Statements - Multus
Multus Comparisons
Competitors of Multus
Multus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioLife Solutions, RoosterBio, Shanghai Doning Biotechnology, ArunA Bio and Biotangents, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Tissue hypothermic storage and cryopreservation freeze media are developed.
|
|
| domain | founded_year | HQ Location |
Developer of human mesenchymal stem cells and extracellular vesicles
|
|
| domain | founded_year | HQ Location |
Serum-free cell culture media is supplied to biopharmaceutical industries.
|
|
| domain | founded_year | HQ Location |
Neural exosome platform is developed for neurodegenerative disease therapeutics.
|
|
| domain | founded_year | HQ Location |
Veterinary diagnostics products are developed for bovine viral diarrhea testing.
|
|
| domain | founded_year | HQ Location |
DNA-based flow reactors are developed for biochemical production.
|
Frequently Asked Questions about Multus
Multus was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Multus is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Cai Linton is the current CEO of Multus. They have also founded this company.
Multus is a funded company, having raised a total of $9.3M across 5 funding rounds to date. The company's 1st funding round was a Grant of $146K, raised on Jun 11, 2020.
As of Mar 31, 2023, the latest employee count at Multus is 8.
Provider of lab-grown meat alternatives. The company claims it is using cells from livestock animals and multiplying them in the laboratory to obtain whole cuts of meat.
Multus's top competitors include FabricNano, RoosterBio and BioLife Solutions.
Multus has 11 investors. Key investors include UK Research and Innovation, European Union, Asahi Kasei, Mandi Ventures, and SOSV.